Searching News Database: schizophrenia
HSMN NewsFeed - 30 Aug 2023
Alkermes Announces Settlement With Teva Related to VIVITROL(R) Patent Litigation
Alkermes Announces Settlement With Teva Related to VIVITROL(R) Patent Litigation
HSMN NewsFeed - 2 Aug 2021
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
HSMN NewsFeed - 11 Mar 2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
HSMN NewsFeed - 30 Oct 2019
Biogen and Alkermes Announce FDA Approval of VUMERITY(TM) (diroximel fumarate) for Multiple Sclerosis
Biogen and Alkermes Announce FDA Approval of VUMERITY(TM) (diroximel fumarate) for Multiple Sclerosis
HSMN NewsFeed - 15 Jul 2019
Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
HSMN NewsFeed - 27 Jun 2019
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
HSMN NewsFeed - 11 Dec 2018
Avanir Pharmaceuticals Announces Termination of License Agreement with Optinose for ONZETRA(R) Xsail(R)
Avanir Pharmaceuticals Announces Termination of License Agreement with Optinose for ONZETRA(R) Xsail(R)
HSMN NewsFeed - 28 May 2018
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
HSMN NewsFeed - 3 Jan 2018
Denovo Biopharma Opens New R&D Center, Names Chief Medical Officer and Chief Financial Officer
Denovo Biopharma Opens New R&D Center, Names Chief Medical Officer and Chief Financial Officer
HSMN NewsFeed - 23 Jun 2017
Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix(R) (vortioxetine) sNDA
Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix(R) (vortioxetine) sNDA
HSMN NewsFeed - 11 Apr 2016
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
HSMN NewsFeed - 12 Jan 2016
Zambon Launches Xadago(R) (Safinamide) in Switzerland for Patients with Parkinson’s Disease
Zambon Launches Xadago(R) (Safinamide) in Switzerland for Patients with Parkinson’s Disease
HSMN NewsFeed - 3 Aug 2015
Omidria(R) Approved for Commercialization Throughout the European Union and Additional Countries
Omidria(R) Approved for Commercialization Throughout the European Union and Additional Countries
HSMN NewsFeed - 15 May 2015
Zambon Launches Xadago(R) (safinamide) for Patients with Mid- to Late-Stage Parkinson’s Disease in Germany
Zambon Launches Xadago(R) (safinamide) for Patients with Mid- to Late-Stage Parkinson’s Disease in Germany
HSMN NewsFeed - 11 May 2015
GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome
GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome
HSMN NewsFeed - 31 Mar 2015
GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome
GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome
HSMN NewsFeed - 3 Jun 2014
Spinifex Pharmaceuticals Appoints Neuroscience Expert Dr Ronald Marcus as Chief Medical Officer
Spinifex Pharmaceuticals Appoints Neuroscience Expert Dr Ronald Marcus as Chief Medical Officer
HSMN NewsFeed - 28 Apr 2014
GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain
GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain
HSMN NewsFeed - 9 Apr 2014
Brainsway's Deep TMS System Will be Exclusively Marketed by Medison Pharma in Israel
Brainsway's Deep TMS System Will be Exclusively Marketed by Medison Pharma in Israel
HSMN NewsFeed - 18 Feb 2014
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction
HSMN NewsFeed - 17 Dec 2013
Zogenix Appoints Chief Medical Officer and Expands Medical Leadership Team
Zogenix Appoints Chief Medical Officer and Expands Medical Leadership Team
HSMN NewsFeed - 2 Dec 2013
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
HSMN NewsFeed - 27 Nov 2013
GW Pharmaceuticals plc Announces Sativex(R) Regulatory Approval in Switzerland
GW Pharmaceuticals plc Announces Sativex(R) Regulatory Approval in Switzerland
HSMN NewsFeed - 21 Nov 2013
Forest Laboratories and Gedeon Richter Receive Complete Response Letter for Cariprazine
Forest Laboratories and Gedeon Richter Receive Complete Response Letter for Cariprazine
HSMN NewsFeed - 30 Sep 2013
FDA Grants Orphan Drug Designation to Omeros' OMS824 for Huntington's Disease
FDA Grants Orphan Drug Designation to Omeros' OMS824 for Huntington's Disease
HSMN NewsFeed - 30 Jul 2013
Alexza Pharmaceuticals Announces European Launch of ADASUVE(R) (Staccato(R) Loxapine)
Alexza Pharmaceuticals Announces European Launch of ADASUVE(R) (Staccato(R) Loxapine)
HSMN NewsFeed - 25 Jul 2013
Promentis Pharmaceuticals, Inc. Appoints Industry Veteran Chad Beyer, Ph.D., MBA, as President and CEO
Promentis Pharmaceuticals, Inc. Appoints Industry Veteran Chad Beyer, Ph.D., MBA, as President and CEO
HSMN NewsFeed - 5 Jul 2013
U.S. FDA Approves Zubsolv(R) for the Maintenance Treatment of Opioid Dependence
U.S. FDA Approves Zubsolv(R) for the Maintenance Treatment of Opioid Dependence
HSMN NewsFeed - 8 May 2013
Teva and Alexza Announce Teva’s License to Market ADASUVE(R) in the U.S.
Teva and Alexza Announce Teva’s License to Market ADASUVE(R) in the U.S.
HSMN NewsFeed - 21 Feb 2013
Alexza Receives Marketing Authorization for ADASUVE(R) (Staccato(R) Loxapine) in the European Union
Alexza Receives Marketing Authorization for ADASUVE(R) (Staccato(R) Loxapine) in the European Union
HSMN NewsFeed - 15 Nov 2012
Targacept Appoints Stephen A. Hill, M.D., President and Chief Executive Officer
Targacept Appoints Stephen A. Hill, M.D., President and Chief Executive Officer
HSMN NewsFeed - 8 Nov 2012
Zogenix Announces FDA Advisory Committee Review of Zohydro(TM) ER for the Management of Chronic Pain
Zogenix Announces FDA Advisory Committee Review of Zohydro(TM) ER for the Management of Chronic Pain
HSMN NewsFeed - 22 Aug 2012
Wockhardt receives tentative US FDA approval for generic version of anti-psychotic drug Geodon(R)
Wockhardt receives tentative US FDA approval for generic version of anti-psychotic drug Geodon(R)
HSMN NewsFeed - 10 Aug 2012
Neuren Appoints Joseph Horrigan, M.D., as VP of Clinical Development and Medical Affairs
Neuren Appoints Joseph Horrigan, M.D., as VP of Clinical Development and Medical Affairs
HSMN NewsFeed - 22 May 2012
EnVivo Pharmaceuticals Appoints Alfred Sandrock, M.D., Ph.D., to Board of Directors
EnVivo Pharmaceuticals Appoints Alfred Sandrock, M.D., Ph.D., to Board of Directors
HSMN NewsFeed - 19 Apr 2012
EnVivo Pharmaceuticals Names Christopher L. Burnley Chief Business Officer
EnVivo Pharmaceuticals Names Christopher L. Burnley Chief Business Officer
HSMN NewsFeed - 27 Feb 2012
European Commission Approves Esmya(R) for the Pre-Operative Treatment of Uterine Fibroids (myomas)
European Commission Approves Esmya(R) for the Pre-Operative Treatment of Uterine Fibroids (myomas)
HSMN NewsFeed - 16 Feb 2012
Mnemosyne Pharmaceuticals, Inc. Completes $5.4 Million Series A Round to Support Drug Discovery Programs
Mnemosyne Pharmaceuticals, Inc. Completes $5.4 Million Series A Round to Support Drug Discovery Programs
HSMN NewsFeed - 30 Nov 2011
SAGE Therapeutics Appoints Chief Scientific Officer, Strengthens Management Team
SAGE Therapeutics Appoints Chief Scientific Officer, Strengthens Management Team
HSMN NewsFeed - 12 Oct 2011
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
HSMN NewsFeed - 9 May 2011
FDA Grants Orphan Drug Designation for Mithridion's MCD-386CR to Treat Progressive Supranuclear Palsy
FDA Grants Orphan Drug Designation for Mithridion's MCD-386CR to Treat Progressive Supranuclear Palsy
HSMN NewsFeed - 9 Feb 2011
Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
HSMN NewsFeed - 21 Dec 2010
Ramius and Royalty Pharma Extend Tender Offer Until January 5, 2011 Pursuant to Definitive Merger Agreement
Ramius and Royalty Pharma Extend Tender Offer Until January 5, 2011 Pursuant to Definitive Merger Agreement
HSMN NewsFeed - 25 Aug 2010
Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial
Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial
HSMN NewsFeed - 14 May 2010
Epizyme Appoints Mikel Moyer, Ph.D., Vice President of Molecular Discovery
Epizyme Appoints Mikel Moyer, Ph.D., Vice President of Molecular Discovery
HSMN NewsFeed - 26 Mar 2010
Cortex Sells Selected AMPAKINE Compounds and Rights to Respiratory Depression Indication to Biovail
Cortex Sells Selected AMPAKINE Compounds and Rights to Respiratory Depression Indication to Biovail
HSMN NewsFeed - 11 Mar 2010
Illumina and Glenn Close Announce the First Full Coverage DNA Sequencing of a Named Female
Illumina and Glenn Close Announce the First Full Coverage DNA Sequencing of a Named Female
HSMN NewsFeed - 8 Mar 2010
Afraxis Appoints Chief Scientific Officer and Vice President, Corporate Development
Afraxis Appoints Chief Scientific Officer and Vice President, Corporate Development
HSMN NewsFeed - 14 Dec 2009
FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
HSMN NewsFeed - 10 Dec 2009
Lundbeck Names Sean Nolan as New CEO of its Lundbeck Inc. U.S. Subsidiary
Lundbeck Names Sean Nolan as New CEO of its Lundbeck Inc. U.S. Subsidiary
HSMN NewsFeed - 4 Dec 2009
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
HSMN NewsFeed - 14 Sep 2009
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
HSMN NewsFeed - 20 Jul 2009
Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
HSMN NewsFeed - 13 May 2009
Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
HSMN NewsFeed - 17 Apr 2009
Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to the Mind Research Network
Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to the Mind Research Network
HSMN NewsFeed - 19 Mar 2009
Cortex Pharmaceuticals Announces Corporate Restructuring and Workforce Reduction
Cortex Pharmaceuticals Announces Corporate Restructuring and Workforce Reduction
HSMN NewsFeed - 23 Feb 2009
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
HSMN NewsFeed - 29 Jan 2009
Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation
HSMN NewsFeed - 26 Jan 2009
Pfizer to Acquire Wyeth, Creating the World's Premier Biopharmaceutical Company
Pfizer to Acquire Wyeth, Creating the World's Premier Biopharmaceutical Company
HSMN NewsFeed - 15 Jan 2009
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
HSMN NewsFeed - 9 Jan 2009
Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB
Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB
HSMN NewsFeed - 10 Oct 2008
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
HSMN NewsFeed - 17 Sep 2008
Memory Pharmaceuticals Realigns Workforce to Support Development Programs
Memory Pharmaceuticals Realigns Workforce to Support Development Programs
HSMN NewsFeed - 16 Sep 2008
Mylan Receives FDA Approval for Generic Version of Anti-Psychotic Risperdal(R)
Mylan Receives FDA Approval for Generic Version of Anti-Psychotic Risperdal(R)
HSMN NewsFeed - 15 Aug 2008
XENAZINE(R) (Tetrabenazine) Approved by FDA for Patients with Chorea Associated with Huntington's Disease
XENAZINE(R) (Tetrabenazine) Approved by FDA for Patients with Chorea Associated with Huntington's Disease
HSMN NewsFeed - 5 Aug 2008
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
HSMN NewsFeed - 4 Aug 2008
Alkermes Announces Approval of VIVITROL(R) for the Treatment of Alcohol Dependence in Russia
Alkermes Announces Approval of VIVITROL(R) for the Treatment of Alcohol Dependence in Russia
HSMN NewsFeed - 31 Jul 2008
Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
HSMN NewsFeed - 28 Jul 2008
FDA Issues Not Approvable Letter for Iloperidone to Vanda Pharmaceuticals
FDA Issues Not Approvable Letter for Iloperidone to Vanda Pharmaceuticals
HSMN NewsFeed - 28 Jul 2008
Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
HSMN NewsFeed - 14 May 2008
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
HSMN NewsFeed - 30 Apr 2008
Titan Pharmaceuticals, Inc. Executive Chairman, Dr. Louis R. Bucalo, Retires to Pursue Other Interests
Titan Pharmaceuticals, Inc. Executive Chairman, Dr. Louis R. Bucalo, Retires to Pursue Other Interests
HSMN NewsFeed - 12 Mar 2008
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
HSMN NewsFeed - 12 Mar 2008
Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
HSMN NewsFeed - 7 Mar 2008
Alkermes Receives Notice from Eli Lilly Terminating Inhaled Insulin Program
Alkermes Receives Notice from Eli Lilly Terminating Inhaled Insulin Program
HSMN NewsFeed - 29 Feb 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
HSMN NewsFeed - 25 Feb 2008
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
HSMN NewsFeed - 18 Jan 2008
Pfizer Statement on CHANTIX (varenicline) Labeling Update in the United States
Pfizer Statement on CHANTIX (varenicline) Labeling Update in the United States
HSMN NewsFeed - 13 Dec 2007
Iloperidone Phase III Clinical Data Demonstrate Efficacy and Favorable Safety and Tolerability Profile
Iloperidone Phase III Clinical Data Demonstrate Efficacy and Favorable Safety and Tolerability Profile
HSMN NewsFeed - 12 Dec 2007
INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
HSMN NewsFeed - 16 Nov 2007
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
HSMN NewsFeed - 14 Nov 2007
Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
HSMN NewsFeed - 30 Oct 2007
Taisho and Pfizer Sign a Letter of Intent for Taisho's Schizophrenia Drug Candidate
Taisho and Pfizer Sign a Letter of Intent for Taisho's Schizophrenia Drug Candidate
HSMN NewsFeed - 22 Oct 2007
Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
HSMN NewsFeed - 16 Oct 2007
Cortex Names Pierre V. Tran, MD, MMM, Chief Medical Officer and Vice President of Clinical Development
Cortex Names Pierre V. Tran, MD, MMM, Chief Medical Officer and Vice President of Clinical Development
HSMN NewsFeed - 12 Oct 2007
Elekta: Finding Hope for Autism - New Brain Research Technology Centre Opened by HRH Princess Anne
Elekta: Finding Hope for Autism - New Brain Research Technology Centre Opened by HRH Princess Anne
HSMN NewsFeed - 10 Oct 2007
NuPathe Inc. Names Jerry McLaughlin as Vice President of Commercial Operations
NuPathe Inc. Names Jerry McLaughlin as Vice President of Commercial Operations
HSMN NewsFeed - 26 Sep 2007
Titan Adds Dr. Marc Rubin to Executive Management Team as President and Chief Executive Officer
Titan Adds Dr. Marc Rubin to Executive Management Team as President and Chief Executive Officer
HSMN NewsFeed - 25 Sep 2007
TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer's Disease
TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer's Disease
HSMN NewsFeed - 27 Aug 2007
BioLineRx In-Licenses Novel Drug for the Treatment of Acute Kidney Injury
BioLineRx In-Licenses Novel Drug for the Treatment of Acute Kidney Injury
HSMN NewsFeed - 8 Aug 2007
Medivation Names Robert Elfont, M.D., Ph.D., Vice President of Clinical Development
Medivation Names Robert Elfont, M.D., Ph.D., Vice President of Clinical Development
HSMN NewsFeed - 3 Jul 2007
Azur Pharma Announces the Acquisition of FazaClo for $42 Million Plus Contingent Milestones
Azur Pharma Announces the Acquisition of FazaClo for $42 Million Plus Contingent Milestones
HSMN NewsFeed - 3 Jul 2007
AVANIR Pharmaceuticals Announces Sale of FazaClo to Fund Continued Development of Zenvia
AVANIR Pharmaceuticals Announces Sale of FazaClo to Fund Continued Development of Zenvia
HSMN NewsFeed - 28 Jun 2007
INVEGA(TM) Receives Marketing Authorization In European Union For Treatment Of Schizophrenia
INVEGA(TM) Receives Marketing Authorization In European Union For Treatment Of Schizophrenia
HSMN NewsFeed - 21 Jun 2007
LAB International licenses Fentanyl TAIFUN(R) to Janssen Pharmaceutica NV for Europe
LAB International licenses Fentanyl TAIFUN(R) to Janssen Pharmaceutica NV for Europe
HSMN NewsFeed - 19 Jun 2007
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia
HSMN NewsFeed - 31 May 2007
AVANIR Receives FDA Approval for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
AVANIR Receives FDA Approval for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
HSMN NewsFeed - 21 May 2007
Siemens Demonstrates World's First System Capable of Simultaneous Imaging of the Brain by MRI and PET
Siemens Demonstrates World's First System Capable of Simultaneous Imaging of the Brain by MRI and PET
HSMN NewsFeed - 20 May 2007
Pfizer Says Research and Development Head John LaMattina Will Retire This Year
Pfizer Says Research and Development Head John LaMattina Will Retire This Year
HSMN NewsFeed - 17 May 2007
Cortex's AMPAKINE(R) Drug May Offer New Hope for Memory Problems Associated with Huntington's Disease
Cortex's AMPAKINE(R) Drug May Offer New Hope for Memory Problems Associated with Huntington's Disease
HSMN NewsFeed - 27 Apr 2007
FDA Approves INVEGA (TM) for Long-Term Maintenance Treatment of Schizophrenia
FDA Approves INVEGA (TM) for Long-Term Maintenance Treatment of Schizophrenia
HSMN NewsFeed - 25 Apr 2007
Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
HSMN NewsFeed - 13 Apr 2007
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
HSMN NewsFeed - 30 Mar 2007
Study Suggests INVEGA(TM) Helps Patients With Schizophrenia Maintain Symptom Control
Study Suggests INVEGA(TM) Helps Patients With Schizophrenia Maintain Symptom Control
HSMN NewsFeed - 20 Mar 2007
Barr Confirms Filing an Application with a Paragraph IV Certification for ABILIFY(R) Tablets
Barr Confirms Filing an Application with a Paragraph IV Certification for ABILIFY(R) Tablets
HSMN NewsFeed - 15 Mar 2007
Alexian Brothers Hospital Network To Bring Advanced Brain Mapping Technology To Chicagoland
Alexian Brothers Hospital Network To Bring Advanced Brain Mapping Technology To Chicagoland
HSMN NewsFeed - 13 Mar 2007
Xytis Enrolls First Patient in Phase II Clinical Study With Anatibant (XY2405) for Traumatic Brain Injury
Xytis Enrolls First Patient in Phase II Clinical Study With Anatibant (XY2405) for Traumatic Brain Injury
HSMN NewsFeed - 15 Feb 2007
Valeant Pharmaceuticals Acquires Rights to Nabilone in United Kingdom and Europe
Valeant Pharmaceuticals Acquires Rights to Nabilone in United Kingdom and Europe
HSMN NewsFeed - 30 Jan 2007
AVANIR Receives FDA Approvable Letter for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
AVANIR Receives FDA Approvable Letter for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
HSMN NewsFeed - 30 Jan 2007
PsychoGenics Announces the Launch of Psylin Neurosciences, Inc. in Partnership with Amylin Pharmaceuticals
PsychoGenics Announces the Launch of Psylin Neurosciences, Inc. in Partnership with Amylin Pharmaceuticals
HSMN NewsFeed - 9 Jan 2007
Xytis Begins Phase II Clinical Study with Anatibant (XY2405) for Traumatic Brain Injury
Xytis Begins Phase II Clinical Study with Anatibant (XY2405) for Traumatic Brain Injury
HSMN NewsFeed - 5 Jan 2007
Xytis Pharmaceuticals Names Dr. Vincent F. Simmon President, Chief Executive Officer and Director
Xytis Pharmaceuticals Names Dr. Vincent F. Simmon President, Chief Executive Officer and Director
HSMN NewsFeed - 4 Jan 2007
Eli Lilly and Company Statement Regarding Today's New York Times Article - January 4, 2007
Eli Lilly and Company Statement Regarding Today's New York Times Article - January 4, 2007
HSMN NewsFeed - 4 Jan 2007
Lilly and Plaintiffs' Attorneys Enter Into Agreements to Settle Zyprexa(R) Product Liability Litigation
Lilly and Plaintiffs' Attorneys Enter Into Agreements to Settle Zyprexa(R) Product Liability Litigation
HSMN NewsFeed - 20 Dec 2006
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
HSMN NewsFeed - 19 Dec 2006
PsychoGenics Announces Drug Discovery and Development Agreement With Eli Lilly and Company
PsychoGenics Announces Drug Discovery and Development Agreement With Eli Lilly and Company
HSMN NewsFeed - 18 Dec 2006
Statement from Eli Lilly and Company: Response to The New York Times Article from December 18, 2006
Statement from Eli Lilly and Company: Response to The New York Times Article from December 18, 2006
HSMN NewsFeed - 1 Dec 2006
Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial
Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial
HSMN NewsFeed - 28 Nov 2006
Neurogen In-licenses Drug Candidate for Parkinson's Disease and Restless Legs Syndrome
Neurogen In-licenses Drug Candidate for Parkinson's Disease and Restless Legs Syndrome
HSMN NewsFeed - 13 Nov 2006
Corcept Therapeutics Completes Enrollment in Third Phase 3 Study for Treating Psychotic Major Depression
Corcept Therapeutics Completes Enrollment in Third Phase 3 Study for Treating Psychotic Major Depression
HSMN NewsFeed - 9 Nov 2006
Targacept Announces Positive Results of Phase II Clinical Trial in Major Depression
Targacept Announces Positive Results of Phase II Clinical Trial in Major Depression
HSMN NewsFeed - 24 Oct 2006
Targacept Announces Addition of Alan W. Dunton, M.D. to Its Board of Directors
Targacept Announces Addition of Alan W. Dunton, M.D. to Its Board of Directors
HSMN NewsFeed - 13 Oct 2006
Neurotechnology Industry Organization Launched to Advance Treatments for Brain and Nervous System Illnesses
Neurotechnology Industry Organization Launched to Advance Treatments for Brain and Nervous System Illnesses
HSMN NewsFeed - 6 Oct 2006
FDA Approves RISPERDAL(R) for Treatment of Irritability Associated with Autistic Disorder
FDA Approves RISPERDAL(R) for Treatment of Irritability Associated with Autistic Disorder
HSMN NewsFeed - 29 Sep 2006
FDA Issues Approvable Letter for Paliperidone ER for the Treatment of Schizophrenia
FDA Issues Approvable Letter for Paliperidone ER for the Treatment of Schizophrenia
HSMN NewsFeed - 18 Jul 2006
AstraZeneca Submits NDA for Sustained Release Formulation of SEROQUEL(R) for Schizophrenia Treatment
AstraZeneca Submits NDA for Sustained Release Formulation of SEROQUEL(R) for Schizophrenia Treatment
HSMN NewsFeed - 30 Jun 2006
EPIX Pharmaceuticals Files Appeal with FDA Regarding Vasovist(TM) Approvable Letters
EPIX Pharmaceuticals Files Appeal with FDA Regarding Vasovist(TM) Approvable Letters
HSMN NewsFeed - 23 May 2006
AVANIR Announces the Intended Acquisition of a Private Specialty Pharmaceutical Company
AVANIR Announces the Intended Acquisition of a Private Specialty Pharmaceutical Company
HSMN NewsFeed - 22 May 2006
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
HSMN NewsFeed - 22 May 2006
Corcept Therapeutics Completes Enrollment in Second Phase 3 Study for Treating Psychotic Major Depression
Corcept Therapeutics Completes Enrollment in Second Phase 3 Study for Treating Psychotic Major Depression
HSMN NewsFeed - 19 May 2006
Targacept Announces Positive Phase II Results for TC-1734 (AZD3480) in Memory Impaired Older Subjects
Targacept Announces Positive Phase II Results for TC-1734 (AZD3480) in Memory Impaired Older Subjects
HSMN NewsFeed - 16 May 2006
Valeant Pharmaceuticals Receives FDA Marketing Approval for Cannabinoid Cesamet(TM) (CII)
Valeant Pharmaceuticals Receives FDA Marketing Approval for Cannabinoid Cesamet(TM) (CII)
HSMN NewsFeed - 5 May 2006
Janssen-Cilag Submits Marketing Authorization Application in Europe for New Treatment for Schizophrenia
Janssen-Cilag Submits Marketing Authorization Application in Europe for New Treatment for Schizophrenia
Additional items found! 216
Members Archive contains
216 additional stories matching:
schizophrenia
(Password required)
schizophrenia
(Password required)